NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics (NASDAQ: NEO) will participate in the Stephens Annual Investment Conference and Piper Sandler 38th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the company will participate in the following investor conferences:
- Stephens Annual Investment Conference in
Nashville, TN
Fireside chat on Tuesday, November 17, 2026, at 8:45 am CST - Piper Sandler 38th Annual Healthcare Conference in
New York, NY
Fireside chat on Tuesday, December 1, 2026, at 4:00 pm EST
Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261106307520/en/
Investor Contact
InvestorRelations@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.